Is SNN a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Smith & Nephew (SNN) rests on Sports Medicine is doing the compounding: Sports Medicine & ENT grew 7.7% underlying in the first half of 2026 to $1,017 million, and 8.6% in the second quarter alone, while the rest of the group was roughly flat. The bear case rests on the clearest risk is that US Orthopaedics does not turn. Analysts covering it publish targets from $30.90 to $38.00 against a $29.83 share price on November 20, 2026, so even the professionals disagree by 21% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

SNN key stats

At $29.83 on November 20, 2026, Smith & Nephew (SNN) has a market cap of $12.5B, a P/E of 20.3 on trailing earnings (12.6 on forward earnings) and a dividend yield of 2.65%.

Market cap
$12.5B
P/E (trailing)
20.3
P/E (forward)
12.6
EPS (trailing 12 months)
$1.47
Price to book
12.3
Dividend yield
2.65%
Beta
0.67

Market cap, P/E and yield are measured at the $29.83 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Smith & Nephew (SNN)?

The last two weeks for Smith & Nephew, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • SNN closed at $29.83 on November 20, 2026, down 4.6% over the past five trading days (from $31.28).
  • On November 18, 2026, Smith & Nephew filed a current report (6-K) with the SEC. Read the 6-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Smith & Nephew sells implants and consumables into the operating room and the wound clinic, and it runs three global business units. Orthopaedics, the largest at $2,437 million of 2025 revenue, covers knee implants, hip implants, other reconstruction and a trauma and extremities line. Sports Medicine & ENT, $1,934 million in 2025, sells arthroscopic repair systems, the REGENETEN bioinductive implant for rotator cuff repair, visualisation and resection hardware, and ear, nose and throat instruments. Advanced Wound Management, $1,793 million, spans foam and antimicrobial dressings, negative pressure wound therapy devices such as PICO and RENASYS, and a bioactives portfolio that includes SANTYL and skin substitutes. Group revenue was $6,164 million in 2025, up 6.1% reported and 5.3% underlying, and the business employs roughly 17,000 people. Around half of sales come from the United States: US revenue was $1,591 million of the $3,097 million booked in the first half of 2026. Emerging markets, where the company grew 10.6% underlying in that half, are the fastest-moving geography and also the source of the China pricing risk described below. The customer is a hospital or a surgical centre, the sale is usually a consumable or an implant rather than a capital item, and revenue is therefore closely tied to elective procedure volumes in the United States, Europe and Japan. What drives the numbers is the gap between the franchises. Sports Medicine & ENT and Advanced Wound Management earned 23.8% and 24.9% segment trading margins in 2025; Orthopaedics earned 14.9%, and in the first half of 2026 it ran at 13.0%. Orthopaedics has been the fix-it project for four years, first through the 12-Point Plan that ran to the end of 2025 and now under the RISE strategy launched in December 2025, which targets a 6% to 7% organic revenue CAGR and a 9% to 10% trading profit CAGR out to 2028. Trading profit, the company's own preferred profit measure, ran at $1,211 million in 2025 against reported operating profit of $794 million, and the difference is restructuring, acquisition amortisation and legal charges that have recurred every year. The market is paying about 20 times trailing reported earnings and roughly 13 times forward consensus earnings for that mix. The shares slid after management cut 2026 revenue growth guidance from around 6% to around 4% on August 4, touched a 52-week low of ~$26.12, and closed at ~$30.06 on November 20, 2026, down ~8.6% for the year and ~6.0% over twelve months. Trading profit, free cash flow and return guidance survived the August cut but not the November one: with third-quarter revenue of ~$1.55 billion, up 3.4% underlying, the company now expects about 3% underlying growth, ~$1.25 billion of trading profit, ~$750 million of free cash flow and ROIC of about 9%. The same update said talks with Johnson & Johnson about a combination involving DePuy Synthes had ended and that the board is evaluating strategic alternatives for Orthopaedics, with no decision or timeline.

The bull case: what would have to be true for $38.00

The most optimistic published target on SNN is $38.00, +27.4% from the $29.83 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Sports Medicine is doing the compounding

Sports Medicine & ENT grew 7.7% underlying in the first half of 2026 to $1,017 million, and 8.6% in the second quarter alone, while the rest of the group was roughly flat. Joint Repair, the largest piece at $574 million, grew 10.3% underlying on REGENETEN and the knee repair portfolio. Segment trading margin rose 160 basis points to 24.7%, so the growth is arriving with operating leverage rather than at the cost of it. In January 2026 the company paid $390 million in fair value consideration for Integrity Orthopaedics and its Tendon Seam rotator cuff repair technology, comprising $225 million of initial cash and $165 million of discounted milestone payments. Management has said it wants to be the global leader in sports medicine, and this is the franchise where the RISE targets are best supported by current trading. The third quarter kept the pace: Sports Medicine & ENT grew 7.9% underlying, joint repair 11.2%, with double-digit US growth across all three segments. Product launches have continued too: the CARTIHEAL AGILI-C cartilage repair implant launched across key European markets in October 2026.

2. Orthopaedics margin ahead of Orthopaedics revenue

Orthopaedics revenue was $1,213 million in the first half of 2026, down 0.1% underlying, with US knee implants falling 7.2% in the second quarter. The stated causes are deliberate portfolio rationalisation, capital discipline on instrument sets, and a market shift toward cementless knees that the company was late to serve. Margin has moved anyway: segment trading profit rose 36.9% in 2025 to $363 million, and the first-half 2026 margin ticked up 30 basis points to 13.0% despite an inventory revaluation headwind. The revenue answer is meant to arrive through product. LEGION MS now accounts for almost 20% of the LEGION mix, LEGION CONCELOC cementless is growing double digits, and the kinematic LANDMARK Knee System is the launch management points at for late 2026 and 2027. In the third quarter Orthopaedics grew 2.5% underlying, with hips and knees strong outside the US and still weak inside it; management blames US knee losses on business lost in earlier periods, including surgeon retirements, and on cementless knees, now nearly 40% of the US market, where its own portfolio is only about 10% cementless. The cementless LANDMARK knee has FDA approval and the cemented version is expected in the second quarter of 2027. Until those ship at scale, the franchise is a margin story attached to a slow revenue line. In trauma, the EVOS PELVIC system launched at the end of September 2026. The board is now evaluating strategic alternatives for the whole Orthopaedics business after talks with Johnson & Johnson about combining it with DePuy Synthes ended, and has given no decision or timeline.

3. Efficiency savings could not absorb a second cut

On August 4, 2026 the company cut expected full-year revenue growth from around 6% to around 4%, and at first left trading profit, free cash flow and return on invested capital guidance unchanged, at roughly $1.3 billion of trading profit after the Integrity acquisition, about $800 million of free cash flow, and adjusted ROIC above 10% excluding Integrity. The offset was $50 million of additional efficiency savings identified during the half, taking planned 2026 savings to around $200 million, and tariffs were expected to be broadly neutral to trading profit net of refunds. Hitting that plan required second-half revenue growth of 5.0% to 5.5%. The third quarter delivered 3.4% underlying, an acceleration from the second quarter but short of that pace, so in November the company cut again: about 3% underlying revenue growth, ~$1.25 billion of trading profit, ~$750 million of free cash flow and ROIC of about 9%. The skin substitute headwind is still expected toward the upper end of its $20 million to $40 million range. Guidance for 2027 is due with fourth-quarter results. Analyst consensus for full-year 2026 sits near $2.15 per ADS on ~$6.41 billion of revenue, and for 2027 near $2.37 on ~$6.72 billion.

4. An activist holder that keeps adding

Cevian Capital filed a Schedule 13D on Smith & Nephew in July 2024, the activist form rather than the passive one. It held 5.02% at the company's February 2026 disclosure date and 119,179,419 ordinary shares, or 14.18% of the 840,515,838 outstanding, by the July 27, 2026 amendment, at a cost of about $1.67 billion. Press reporting has it above 14.2% in early August. Investors including Cevian have publicly pressed the board to consider separating the businesses. In November 2026 the company confirmed that talks with Johnson & Johnson about a combination involving DePuy Synthes had ended and that it is evaluating strategic alternatives for Orthopaedics; no separation, break-up or sale has been announced. Management's capital response so far has been cash returns: a $500 million buyback announced in May 2026 with $250 million completed by the end of the third quarter and Merrill Lynch retained in November to execute a further $250 million tranche, following a $500 million programme run in the second half of 2025, plus an interim dividend raised 4.0% to 15.6 cents.

The bear case: what would have to be true for $30.90

The most pessimistic published target is $30.90, +3.6% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Smith & Nephew is worth if the risks below bite instead of the drivers above.

The clearest risk is that US Orthopaedics does not turn. Knee implants fell 7.2% in the US in the second quarter of 2026, US hips and knees were still weak in the third, and the fix depends on launches, principally LANDMARK and wider LEGION MS set deployment, that mostly land in 2027. Launches slip, surgeons switch slowly, and a competitor with four times the revenue can out-spend the response. Advanced Wound Bioactives is the second pressure point: revenue fell 8.1% underlying in the first half and 8.8% in the third quarter after the January 2026 US reimbursement reset on skin substitutes, and the full-year headwind is now expected toward the upper end of a $20 million to $40 million range. China is a third. Volume-based procurement has already compressed sports medicine pricing, the ENT tender process has been delayed into the second half of 2026, and the company has been running down channel inventory ahead of it, so the reported growth in that market is not a clean read on demand. Execution risk sits on top of all of it: the company has now cut 2026 guidance twice, in August and November, and the second cut reached trading profit, free cash flow and ROIC as well as revenue. The strategic review of Orthopaedics adds uncertainty in both directions, since the Johnson & Johnson talks ended without a deal. RBC cut its price target to GBP 11.50 from GBP 12.50 in November. There is a governance gap as well. CFO John Rogers resigned on August 19, 2026 and left on September 30; Pierre Palassian is interim CFO while the search continues. Cevian's 14.2% position could force portfolio action or leave a large overhang if the thesis is abandoned. Legacy metal-on-metal hip claims still carry provisions, adjusted net debt to EBITDA was 1.8 times at the half, and $350 million of corporate bonds plus $140 million of private placement debt fall due in the first half of 2027.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding SNN already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on SNN

5 analysts cover SNN, with an average target of $33.19 (+11.3% against $29.83) and a split of 1 buy, 5 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the SNN forecast and price target page.

How is SNN valued?

Market cap, P/E and dividend yield at today's price are in the SNN key stats above. The business figures below come from Smith & Nephew's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$6.30 billion for the twelve months to June 27, 2026 (the latest period with full financial statements), against $6,164 million in 2025, up 6.1% reported and 5.3% underlying, and $5,810 million in 2024. First-half 2026 growth was 4.6% reported but only 2.3% underlying. Third-quarter 2026 revenue was ~$1.55 billion, up 3.4% on both underlying and reported bases. Everything here is reported in US dollars, the company's actual reporting currency, so no conversion from sterling is involved.
  • Earnings and adjusted earnings: Attributable profit of ~$635 million on a trailing basis, giving roughly $1.47 per ADS at the two-for-one ratio (~73-74 cents per ordinary share). Full-year 2025 EPS was 72.1 cents per ordinary share on operating profit of $794 million. The company's preferred measure runs well above that: trading profit was $1,211 million in 2025 (19.7% margin), with adjusted EPS of 102.0 cents per ordinary share, about $2.04 per ADS. 2026 trading profit guidance is now ~$1.25 billion. The gap between operating and trading profit, roughly $440 million in 2025, is restructuring, acquisition amortisation and legal items.
  • Franchise growth and margins: 2025 segment trading margins were 14.9% for Orthopaedics, 23.8% for Sports Medicine & ENT and 24.9% for Advanced Wound Management. Third-quarter 2026 underlying growth was Orthopaedics +2.5%, Sports Medicine & ENT +7.9% (joint repair +11.2%) and Advanced Wound Management -0.2% (Bioactives -8.8%). By geography, the US grew 3%, other established markets 3.2% and emerging markets 4.8%.
  • Cash flow and balance sheet: Free cash flow of ~$1.06 billion on Yahoo Finance's trailing basis and $836 million in 2025; 2026 guidance is now ~$750 million, down from ~$800 million. Total debt is ~$3.78 billion against ~$754 million of cash, and adjusted net debt to EBITDA was 1.8 times at the half. $350 million of corporate bonds and $140 million of private placement notes fall due in the first half of 2027.
  • Market pricing: The ADS closed at ~$30.06 on November 20, 2026, against a 52-week range of ~$26.12 to ~$37.09, down ~8.6% year to date and ~6.0% over one year. Market capitalisation is ~$12.6 billion. The dividend rate of ~$0.79 per ADS is a yield of ~2.7%, with a payout ratio near 53% of trailing earnings.
  • Guidance and 2028 targets: 2026 guidance was cut twice: in August revenue growth went to around 4% from around 6%, and in November to about 3% underlying, with trading profit lowered to ~$1.25 billion from ~$1.3 billion, free cash flow to ~$750 million from ~$800 million and ROIC to about 9%. The RISE strategy of December 2025 targets a 6% to 7% organic revenue CAGR and 9% to 10% trading profit CAGR through 2028, against 2025 adjusted ROIC of 8.3%. 2027 guidance comes with fourth-quarter results.

As of November 2026: The multiple sits well below the large-cap orthopaedic peer group, and the reason is visible in the segment table more than in any accounting subtlety: the largest franchise earns the lowest margin and grows slowest. At ~13 times forward consensus earnings in November 2026, after two guidance cuts and the end of talks with Johnson & Johnson, investors are paying for the RISE targets to close that gap, or for the Orthopaedics strategic review to force the issue on portfolio structure. Five covering analysts carry a mean target of ~$33.19 and a hold rating.

How do you decide if SNN is a buy?

Whether SNN is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold SNN indirectly through an index or sector ETF before adding more.

What would change your mind on SNN

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Sports Medicine is doing the compounding stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: the clearest risk is that US Orthopaedics does not turn fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the SNN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SNN against your real portfolio and see your actual exposure before deciding.

Your questions about Smith & Nephew

Ask Walnut's AI anything about SNN and see how it fits what you own.

FAQ

Is SNN a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Sports Medicine is doing the compounding, with revenue (ttm) at ~$6.30 billion for the twelve months to June 27, 2026 (the latest period with full financial statements), against $6,164 million in 2025, up 6.1% reported and 5.3% underlying, and $5,810 million in 2024. First-half 2026 growth was 4.6% reported but only 2.3% underlying. Third-quarter 2026 revenue was ~$1.55 billion, up 3.4% on both underlying and reported bases. Everything here is reported in US dollars, the company's actual reporting currency, so no conversion from sterling is involved.. The bear case rests on the clearest risk is that US Orthopaedics does not turn. Analysts covering it are spread from $30.90 to $38.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell SNN?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The clearest risk is that US Orthopaedics does not turn. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $30.90, +3.6% from the $29.83 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for SNN?

+

Sports Medicine is doing the compounding. Sports Medicine & ENT grew 7.7% underlying in the first half of 2026 to $1,017 million, and 8.6% in the second quarter alone, while the rest of the group was roughly flat. The most optimistic analyst target on SNN is $38.00, +27.4% from the $29.83 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for SNN?

+

The clearest risk is that US Orthopaedics does not turn. Knee implants fell 7.2% in the US in the second quarter of 2026, US hips and knees were still weak in the third, and the fix depends on launches, principally LANDMARK and wider LEGION MS set deployment, that mostly land in 2027. Launches slip, surgeons switch slowly, and a competitor with four times the revenue can out-spend the response. Advanced Wound Bioactives is the second pressure point: revenue fell 8.1% underlying in the first half and 8.8% in the third quarter after the January 2026 US reimbursement reset on skin substitutes, and the full-year headwind is now expected toward the upper end of a $20 million to $40 million range. China is a third. Volume-based procurement has already compressed sports medicine pricing, the ENT tender process has been delayed into the second half of 2026, and the company has been running down channel inventory ahead of it, so the reported growth in that market is not a clean read on demand. Execution risk sits on top of all of it: the company has now cut 2026 guidance twice, in August and November, and the second cut reached trading profit, free cash flow and ROIC as well as revenue. The strategic review of Orthopaedics adds uncertainty in both directions, since the Johnson & Johnson talks ended without a deal. RBC cut its price target to GBP 11.50 from GBP 12.50 in November. There is a governance gap as well. CFO John Rogers resigned on August 19, 2026 and left on September 30; Pierre Palassian is interim CFO while the search continues. Cevian's 14.2% position could force portfolio action or leave a large overhang if the thesis is abandoned. Legacy metal-on-metal hip claims still carry provisions, adjusted net debt to EBITDA was 1.8 times at the half, and $350 million of corporate bonds plus $140 million of private placement debt fall due in the first half of 2027. The most pessimistic published target is $30.90, +3.6% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does Smith & Nephew do?

+

Smith & Nephew is a UK medical-device maker listed in New York as an ADR, spanning orthopedics, sports medicine and advanced wound management.

What would have to change for SNN to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Sports Medicine is doing the compounding) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the clearest risk is that US Orthopaedics does not turn) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Smith & Nephew do?

+

Smith & Nephew is a medical technology company that makes products used in surgery and wound care, organised into three global business units. Orthopaedics supplies knee and hip implants, other reconstruction products, and trauma and extremities hardware, and generated $2,437 million of revenue in 2025. Sports Medicine & ENT sells arthroscopic repair implants and instruments, visualisation and tissue resection equipment, and ear, nose and throat devices, at $1,934 million. Advanced Wound Management covers foam and antimicrobial dressings, negative pressure wound therapy systems including PICO and RENASYS, and a bioactives range that includes SANTYL and skin substitutes, at $1,793 million. Group revenue was $6,164 million in 2025 and roughly $6.30 billion for the twelve months to June 27, 2026; third-quarter 2026 revenue was ~$1.55 billion. The company employs about 17,000 people and is headquartered in Watford, England.

Is SNN an ADR, and how many shares does each one represent?

+

SNN on the New York Stock Exchange is an American Depositary Share, and each ADS represents two ordinary shares of Smith & Nephew plc. J.P. Morgan Chase Bank N.A. is the depositary bank. The company's primary listing is on the London Stock Exchange under the ticker SN, and the ordinary shares also trade over the counter in the US as SNNUF. The two-for-one ratio is the single most common source of error when comparing figures across the two lines. Company filings report earnings and dividends per ordinary share, so the 2025 dividend of 39.1 cents per ordinary share is 78.2 cents per ADS, and 2025 adjusted EPS of 102.0 cents per ordinary share is about $2.04 per ADS. Any yield or P/E built on London per-share data and a New York price will be wrong by a factor of two.

Why did SNN stock drop in 2026?

+

The stock spent 2026 giving back a 2025 gain of 28%, fell to a 52-week low of ~$26.12 after the August results, and closed at ~$30.06 on November 20, 2026, down ~8.6% for the year and below the ~$37.09 52-week high. The first cause was the August 4, 2026 half-year results, at which management cut full-year revenue growth guidance from around 6% to around 4%. First-half underlying growth was 2.3%, US knee implants fell 7.2% in the second quarter, and Advanced Wound Bioactives revenue fell 8.1% underlying after a US reimbursement change on skin substitutes took effect in January. Profit guidance held at first, helped by an extra $50 million of cost savings, but the November third-quarter update cut it too: about 3% underlying revenue growth, ~$1.25 billion of trading profit, ~$750 million of free cash flow and ROIC of about 9%. The same update said talks with Johnson & Johnson over a DePuy Synthes combination had ended.

Walnut is informational, not investment advice, and gives no verdict on SNN. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks